<!DOCTYPE html>
  <html lang="en">
    <head>
    <meta charset="UTF-8" />
      <title>SPRINT Trial – Statistical Review</title>
      <meta name="viewport" content="width=device-width, initial-scale=1.0" />
        <link rel="stylesheet" href="/css/stat-reviews.css" /> 
          <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
            <script id="MathJax-script" async 
            src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js">
              </script>
              </head>
              <body>
              <main class="review-content">
              <div id="doc" class="markdown-body container-fluid comment-inner comment-enabled" data-hard-breaks="true" lang="en-US"><p class="part in-view" data-startline="1" data-endline="2" data-position="0" data-size="0"><span data-position="0" data-size="66">title: "Statistical and Methodological Review of the SPRINT Trial"</span><br>
              <span data-position="67" data-size="14">version: "1.5"</span></p><h2 class="part in-view" data-startline="4" data-endline="9" id="Reviewer-Robert-Long-Position-Principal-Consultant-Company-The-Data-Guru-Ltd-Date-18-May-2025-Document-Version-15" data-id="Reviewer-Robert-Long-Position-Principal-Consultant-Company-The-Data-Guru-Ltd-Date-18-May-2025-Document-Version-15"><a class="anchor hidden-xs" href="#Reviewer-Robert-Long-Position-Principal-Consultant-Company-The-Data-Guru-Ltd-Date-18-May-2025-Document-Version-15" title="Reviewer-Robert-Long-Position-Principal-Consultant-Company-The-Data-Guru-Ltd-Date-18-May-2025-Document-Version-15" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="83" data-size="21">Reviewer: Robert Long</span><br>
              <span data-position="107" data-size="30">Position: Principal Consultant</span><br>
              <span data-position="140" data-size="26">Company: The Data Guru Ltd</span><br>
              <span data-position="169" data-size="17">Date: 18 May 2025</span><br>
              <span data-position="189" data-size="21">Document Version: 1.5</span></h2><h2 class="part in-view" data-startline="11" data-endline="11" id="I-Introduction-amp-Background" data-id="I-Introduction-amp-Background"><a class="anchor hidden-xs" href="#I-Introduction-amp-Background" title="I-Introduction-amp-Background" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="219" data-size="28">I. Introduction &amp; Background</span></h2><p class="part in-view" data-startline="13" data-endline="13" data-position="249" data-size="0"><span data-position="249" data-size="4">The </span><strong data-position="253" data-size="0"><span data-position="255" data-size="51">Systolic Blood Pressure Intervention Trial (SPRINT)</span></strong><span data-position="308" data-size="254">, published by Wright et al. (2015), was a landmark randomised controlled trial (RCT) investigating whether systolic blood pressure (SBP) targets for high-risk, non-diabetic patients should be lowered to &lt;120 mm Hg rather than the traditional &lt;140 mm Hg.</span></p><p class="part in-view" data-startline="15" data-endline="15" data-position="564" data-size="0"><span data-position="564" data-size="296">At the time, international guidelines varied considerably, driven by inconclusive evidence from earlier trials such as ACCORD-BP (ACCORD Study Group, 2010) and HYVET (Beckett et al., 2008). SPRINT influenced guidelines notably in the United States, recommending stricter SBP control (&lt;130 mm Hg).</span></p><p class="part in-view" data-startline="17" data-endline="17" data-position="862" data-size="0"><span data-position="862" data-size="276">This review critically evaluates the trial’s statistical methods, design, outcomes, and implications. It draws upon primary and ancillary trial publications, meta-analyses, and key reappraisals, most notably Wright et al. (2021), who address several methodological criticisms.</span></p><hr class=""><h2 class="part" data-startline="21" data-endline="21" id="II-Trial-Design-and-Methodology" data-id="II-Trial-Design-and-Methodology"><a class="anchor hidden-xs" href="#II-Trial-Design-and-Methodology" title="II-Trial-Design-and-Methodology" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="1148" data-size="32">II. Trial Design and Methodology</span></h2><p class="part" data-startline="23" data-endline="23" data-position="1182" data-size="0"><span data-position="1182" data-size="318">SPRINT was a publicly funded, multi-centre, open-label RCT with blinded outcome adjudication. It was conducted at 102 clinical sites in the United States and enrolled 9,361 participants aged ≥50 years at elevated cardiovascular risk. Key exclusions included diabetes mellitus and prior stroke (Ambrosius et al., 2014).</span></p><p class="part" data-startline="25" data-endline="25" data-position="1502" data-size="0"><span data-position="1502" data-size="32">Participants were randomised to:</span></p><ul class="part" data-startline="26" data-endline="28" data-position="1535" data-size="0">
              <li class="" data-startline="26" data-endline="26" data-position="1537" data-size="0"><strong data-position="1537" data-size="0"><span data-position="1539" data-size="19">Intensive treatment</span></strong><span data-position="1560" data-size="23">: SBP target &lt;120 mm Hg</span></li>
              <li class="" data-startline="27" data-endline="28" data-position="1588" data-size="0"><strong data-position="1588" data-size="0"><span data-position="1590" data-size="18">Standard treatment</span></strong><span data-position="1610" data-size="23">: SBP target &lt;140 mm Hg</span></li>
              </ul><p class="part" data-startline="29" data-endline="29" data-position="1635" data-size="0"><span data-position="1635" data-size="338">Randomisation was stratified by site, age group, cardiovascular disease (CVD), and chronic kidney disease (CKD) status. Blood pressure was measured using the automated Omron HEM-907XL device. Wright et al. (2021) clarified that most measurements were taken unattended to minimise white-coat effects, although some site variation occurred.</span></p><h3 class="part" data-startline="31" data-endline="31" id="Inclusion-and-Exclusion-Criteria" data-id="Inclusion-and-Exclusion-Criteria"><a class="anchor hidden-xs" href="#Inclusion-and-Exclusion-Criteria" title="Inclusion-and-Exclusion-Criteria" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="1979" data-size="32">Inclusion and Exclusion Criteria</span></h3><p class="part" data-startline="33" data-endline="33" data-position="2013" data-size="0"><strong data-position="2013" data-size="0"><span data-position="2015" data-size="8">Included</span></strong><span data-position="2025" data-size="1">:</span></p><ul class="part" data-startline="34" data-endline="37" data-position="2029" data-size="0">
              <li class="raw" data-startline="34" data-endline="34" data-position="2031" data-size="0"><span data-position="2031" data-size="13">Age ≥50 years</span></li>
              <li class="raw" data-startline="35" data-endline="35" data-position="2049" data-size="0"><span data-position="2049" data-size="17">SBP 130–180 mm Hg</span></li>
              <li class="raw" data-startline="36" data-endline="37" data-position="2071" data-size="0"><span data-position="2071" data-size="107">At least one CV risk factor: existing CVD, CKD (eGFR 20–60), age ≥75 years, or Framingham 10-year risk ≥15%</span></li>
              </ul><p class="part" data-startline="38" data-endline="38" data-position="2180" data-size="0"><strong data-position="2180" data-size="0"><span data-position="2182" data-size="8">Excluded</span></strong><span data-position="2192" data-size="1">:</span></p><ul class="part" data-startline="39" data-endline="43" data-position="2196" data-size="0">
              <li class="raw" data-startline="39" data-endline="39" data-position="2198" data-size="0"><span data-position="2198" data-size="17">Diabetes mellitus</span></li>
              <li class="raw" data-startline="40" data-endline="40" data-position="2220" data-size="0"><span data-position="2220" data-size="12">Prior stroke</span></li>
              <li class="raw" data-startline="41" data-endline="41" data-position="2237" data-size="0"><span data-position="2237" data-size="38">LVEF &lt;35% or symptomatic heart failure</span></li>
              <li class="raw" data-startline="42" data-endline="43" data-position="2280" data-size="0"><span data-position="2280" data-size="23">Significant proteinuria</span></li>
              </ul><p class="part" data-startline="44" data-endline="44" data-position="2305" data-size="0"><span data-position="2305" data-size="306">SPRINT was planned to run for five years but was stopped early (median 3.26 years) following interim analysis showing significant benefit (Williamson et al., 2019). Although stopping was pre-specified, early termination raises concern about overestimation of treatment effects (ie., inflated type I error).</span></p><h3 class="part" data-startline="46" data-endline="46" id="Outcomes" data-id="Outcomes"><a class="anchor hidden-xs" href="#Outcomes" title="Outcomes" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="2617" data-size="8">Outcomes</span></h3><p class="part" data-startline="48" data-endline="48" data-position="2627" data-size="0"><strong data-position="2627" data-size="0"><span data-position="2629" data-size="17">Primary composite</span></strong><span data-position="2648" data-size="1">:</span></p><ul class="part" data-startline="49" data-endline="54" data-position="2652" data-size="0">
              <li class="raw" data-startline="49" data-endline="49" data-position="2654" data-size="0"><span data-position="2654" data-size="21">Myocardial infarction</span></li>
              <li class="raw" data-startline="50" data-endline="50" data-position="2680" data-size="0"><span data-position="2680" data-size="40">Acute coronary syndrome (ACS) without MI</span></li>
              <li class="raw" data-startline="51" data-endline="51" data-position="2725" data-size="0"><span data-position="2725" data-size="6">Stroke</span></li>
              <li class="raw" data-startline="52" data-endline="52" data-position="2736" data-size="0"><span data-position="2736" data-size="33">Acute decompensated heart failure</span></li>
              <li class="raw" data-startline="53" data-endline="54" data-position="2774" data-size="0"><span data-position="2774" data-size="20">Cardiovascular death</span></li>
              </ul><p class="part" data-startline="55" data-endline="55" data-position="2796" data-size="0"><strong data-position="2796" data-size="0"><span data-position="2798" data-size="18">Secondary outcomes</span></strong><span data-position="2818" data-size="1">:</span></p><ul class="part" data-startline="56" data-endline="59" data-position="2822" data-size="0">
              <li class="raw" data-startline="56" data-endline="56" data-position="2824" data-size="0"><span data-position="2824" data-size="19">All-cause mortality</span></li>
              <li class="raw" data-startline="57" data-endline="57" data-position="2848" data-size="0"><span data-position="2848" data-size="41">Renal endpoints (eGFR decline, AKI, ESRD)</span></li>
              <li class="raw" data-startline="58" data-endline="59" data-position="2894" data-size="0"><span data-position="2894" data-size="31">Cognitive decline (SPRINT MIND)</span></li>
              </ul><hr><h2 class="part" data-startline="62" data-endline="62" id="III-Main-Findings-and-Outcomes" data-id="III-Main-Findings-and-Outcomes"><a class="anchor hidden-xs" href="#III-Main-Findings-and-Outcomes" title="III-Main-Findings-and-Outcomes" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="2935" data-size="31">III. Main Findings and Outcomes</span></h2><p class="part" data-startline="64" data-endline="64" data-position="2968" data-size="0"><span data-position="2968" data-size="108">The intensive treatment group demonstrated a significantly lower incidence of the primary composite outcome:</span></p><p class="part" data-startline="66" data-endline="68" data-position="3078" data-size="0"><span class="mathjax raw">\[
                \text{HR} = 0.75,\quad 95\%~\text{CI} = [0.64, 0.89],\quad p &lt; 0.001
                \]</span></p><p class="part" data-startline="70" data-endline="70" data-position="3154" data-size="0"><span data-position="3154" data-size="51">All-cause mortality was also significantly reduced:</span></p><p class="part" data-startline="72" data-endline="74" data-position="3207" data-size="0"><span class="mathjax raw">\[
                  \text{HR} = 0.73,\quad 95\%~\text{CI} = [0.60, 0.90],\quad p &lt; 0.004
                  \]</span></p><h3 class="part" data-startline="76" data-endline="76" id="Secondary-and-Ancillary-Outcomes" data-id="Secondary-and-Ancillary-Outcomes"><a class="anchor hidden-xs" href="#Secondary-and-Ancillary-Outcomes" title="Secondary-and-Ancillary-Outcomes" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="3287" data-size="32">Secondary and Ancillary Outcomes</span></h3><ul class="part" data-startline="78" data-endline="83" data-position="3321" data-size="0">
              <li class="raw" data-startline="78" data-endline="78" data-position="3323" data-size="0"><strong data-position="3323" data-size="0"><span data-position="3325" data-size="26">Heart failure and CV death</span></strong><span data-position="3353" data-size="28"> were significantly reduced.</span></li>
              <li class="raw" data-startline="79" data-endline="79" data-position="3384" data-size="0"><strong data-position="3384" data-size="0"><span data-position="3386" data-size="6">Stroke</span></strong><span data-position="3394" data-size="48"> was not significantly different between groups.</span></li>
              <li class="raw" data-startline="80" data-endline="80" data-position="3445" data-size="0"><strong data-position="3445" data-size="0"><span data-position="3447" data-size="14">Renal outcomes</span></strong><span data-position="3463" data-size="115">: Increased incident CKD in non-CKD subgroup; declines were largely haemodynamic and reversible (Hu &amp; Chang, 2021).</span></li>
              <li class="raw" data-startline="81" data-endline="81" data-position="3581" data-size="0"><strong data-position="3581" data-size="0"><span data-position="3583" data-size="32">Cognitive outcomes (SPRINT MIND)</span></strong><span data-position="3617" data-size="142">: Reduced mild cognitive impairment (MCI), but no statistically significant difference in probable dementia (SPRINT MIND Investigators, 2019).</span></li>
              <li class="raw" data-startline="82" data-endline="83" data-position="3762" data-size="0"><strong data-position="3762" data-size="0"><span data-position="3764" data-size="22">Ambulatory BP substudy</span></strong><span data-position="3788" data-size="151">: Intensive group had lower 24-hour, daytime, and nighttime BP. Clinic-based measurements overestimated the ambulatory BP benefit (Drawz et al., 2017).</span></li>
              </ul><hr><h2 class="part" data-startline="86" data-endline="86" id="IV-Critical-Appraisal" data-id="IV-Critical-Appraisal"><a class="anchor hidden-xs" href="#IV-Critical-Appraisal" title="IV-Critical-Appraisal" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="3949" data-size="22">IV. Critical Appraisal</span></h2><h3 class="part" data-startline="88" data-endline="88" id="Internal-Validity" data-id="Internal-Validity"><a class="anchor hidden-xs" href="#Internal-Validity" title="Internal-Validity" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="3977" data-size="17">Internal Validity</span></h3><p class="part" data-startline="90" data-endline="90" data-position="3996" data-size="0"><span data-position="3996" data-size="42">SPRINT exhibited strong internal validity:</span></p><ul class="part" data-startline="91" data-endline="94" data-position="4039" data-size="0">
              <li class="raw" data-startline="91" data-endline="91" data-position="4041" data-size="0"><span data-position="4041" data-size="55">Randomisation and allocation concealment were rigorous.</span></li>
              <li class="raw" data-startline="92" data-endline="92" data-position="4099" data-size="0"><span data-position="4099" data-size="66">BP measurement was mostly unattended, mitigating measurement bias.</span></li>
              <li class="raw" data-startline="93" data-endline="94" data-position="4168" data-size="0"><span data-position="4168" data-size="56">Outcomes were adjudicated blind to treatment allocation.</span></li>
              </ul><p class="part" data-startline="95" data-endline="95" data-position="4226" data-size="0"><span data-position="4226" data-size="119">However, the early stopping, though planned, likely led to modest overestimation of effect sizes (Wright et al., 2021).</span></p><h3 class="part" data-startline="97" data-endline="97" id="External-Validity" data-id="External-Validity"><a class="anchor hidden-xs" href="#External-Validity" title="External-Validity" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="4351" data-size="17">External Validity</span></h3><p class="part" data-startline="99" data-endline="99" data-position="4370" data-size="0"><span data-position="4370" data-size="54">The trial’s exclusion criteria limit generalisability:</span></p><ul class="part" data-startline="100" data-endline="103" data-position="4425" data-size="0">
              <li class="raw" data-startline="100" data-endline="100" data-position="4427" data-size="0"><span data-position="4427" data-size="48">No participants with diabetes or previous stroke</span></li>
              <li class="raw" data-startline="101" data-endline="101" data-position="4478" data-size="0"><span data-position="4478" data-size="57">Limited representation of women (35.6%) and frail elderly</span></li>
              <li class="raw" data-startline="102" data-endline="103" data-position="4538" data-size="0"><span data-position="4538" data-size="65">Under-representation of patients with advanced CKD or proteinuria</span></li>
              </ul><p class="part" data-startline="104" data-endline="104" data-position="4605" data-size="0"><span data-position="4605" data-size="182">Wright et al. (2021) defend these exclusions as necessary for internal validity, but real-world applicability—particularly in general practice and geriatric care—remains constrained.</span></p><h3 class="part" data-startline="106" data-endline="106" id="Composite-Outcomes" data-id="Composite-Outcomes"><a class="anchor hidden-xs" href="#Composite-Outcomes" title="Composite-Outcomes" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="4793" data-size="18">Composite Outcomes</span></h3><p class="part" data-startline="108" data-endline="108" data-position="4813" data-size="0"><span data-position="4813" data-size="281">The primary outcome combined events of varying clinical severity. Benefits were largely driven by heart failure and cardiovascular death. Stroke and ACS without MI contributed minimally. Wright et al. (2021) do not explicitly address this imbalance, which affects interpretability.</span></p><h3 class="part" data-startline="110" data-endline="110" id="Harms-and-Adverse-Events" data-id="Harms-and-Adverse-Events"><a class="anchor hidden-xs" href="#Harms-and-Adverse-Events" title="Harms-and-Adverse-Events" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="5100" data-size="24">Harms and Adverse Events</span></h3><p class="part" data-startline="112" data-endline="112" data-position="5126" data-size="0"><span data-position="5126" data-size="45">Intensive treatment increased adverse events:</span></p><ul class="part" data-startline="113" data-endline="117" data-position="5172" data-size="0">
              <li class="raw" data-startline="113" data-endline="113" data-position="5174" data-size="0"><span data-position="5174" data-size="11">Hypotension</span></li>
              <li class="raw" data-startline="114" data-endline="114" data-position="5190" data-size="0"><span data-position="5190" data-size="7">Syncope</span></li>
              <li class="raw" data-startline="115" data-endline="115" data-position="5202" data-size="0"><span data-position="5202" data-size="24">Electrolyte disturbances</span></li>
              <li class="raw" data-startline="116" data-endline="117" data-position="5231" data-size="0"><span data-position="5231" data-size="35">Acute kidney injury (4.4% vs. 2.6%)</span></li>
              </ul><p class="part" data-startline="118" data-endline="118" data-position="5268" data-size="0"><span data-position="5268" data-size="260">While Wright et al. (2021) argue these were manageable, in older or comorbid patients they represent important clinical harms. These risks must be carefully weighed in practice, especially among those at higher risk of falls, volume depletion, or polypharmacy.</span></p><h3 class="part" data-startline="120" data-endline="120" id="Blood-Pressure-Measurement" data-id="Blood-Pressure-Measurement"><a class="anchor hidden-xs" href="#Blood-Pressure-Measurement" title="Blood-Pressure-Measurement" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="5534" data-size="26">Blood Pressure Measurement</span></h3><p class="part" data-startline="122" data-endline="122" data-position="5562" data-size="0"><span data-position="5562" data-size="371">SPRINT employed mostly unattended, automated office BP. Critics argue this is not reflective of routine clinical practice. Wright et al. (2021) clarify that most sites followed the protocol, reducing white-coat effects. Nonetheless, BP measured in usual care settings may not mirror trial conditions, and directly applying the &lt;120 mm Hg target may lead to overtreatment.</span></p><hr><h2 class="part" data-startline="126" data-endline="126" id="V-Clinical-and-Policy-Implications" data-id="V-Clinical-and-Policy-Implications"><a class="anchor hidden-xs" href="#V-Clinical-and-Policy-Implications" title="V-Clinical-and-Policy-Implications" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="5943" data-size="35">V. Clinical and Policy Implications</span></h2><p class="part" data-startline="128" data-endline="128" data-position="5980" data-size="0"><span data-position="5980" data-size="271">SPRINT reshaped hypertension management, particularly in the US, where guidelines now recommend SBP &lt;130 mm Hg for high-risk individuals. European and UK guidelines have adopted a more conservative approach, citing concerns about generalisability and measurement methods.</span></p><p class="part" data-startline="130" data-endline="130" data-position="6253" data-size="0"><span data-position="6253" data-size="33">Clinical implementation requires:</span></p><ul class="part" data-startline="131" data-endline="134" data-position="6287" data-size="0">
              <li class="raw" data-startline="131" data-endline="131" data-position="6289" data-size="0"><span data-position="6289" data-size="75">Consideration of measurement technique (preferably automated or ambulatory)</span></li>
              <li class="raw" data-startline="132" data-endline="132" data-position="6367" data-size="0"><span data-position="6367" data-size="71">Individualised treatment plans accounting for frailty and comorbidities</span></li>
              <li class="raw" data-startline="133" data-endline="134" data-position="6441" data-size="0"><span data-position="6441" data-size="69">Shared decision-making, especially in older adults and those with CKD</span></li>
              </ul><hr><h2 class="part" data-startline="137" data-endline="137" id="VI-Conclusions" data-id="VI-Conclusions"><a class="anchor hidden-xs" href="#VI-Conclusions" title="VI-Conclusions" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="6520" data-size="15">VI. Conclusions</span></h2><p class="part" data-startline="139" data-endline="139" data-position="6537" data-size="0"><span data-position="6537" data-size="332">SPRINT was a methodologically robust and influential trial, demonstrating that intensive SBP lowering (&lt;120 mm Hg) reduces cardiovascular events and mortality in non-diabetic, high-risk patients. Despite early stopping and concerns about generalisability and adverse events, the core findings are compelling and clinically relevant.</span></p><p class="part" data-startline="141" data-endline="141" data-position="6871" data-size="0"><span data-position="6871" data-size="298">Translating these results into real-world practice demands attention to BP measurement technique, risk–benefit evaluation, and patient-centred care. Wright et al. (2021) address many criticisms of the trial and reaffirm its major contributions, but caution remains warranted in broader application.</span></p><hr><h2 class="part" data-startline="145" data-endline="145" id="References" data-id="References"><a class="anchor hidden-xs" href="#References" title="References" smoothhashscroll=""><span class="octicon octicon-link ph ph-link-simple-horizontal"></span></a><span data-position="7179" data-size="10">References</span></h2><p class="part" data-startline="147" data-endline="147" data-position="7191" data-size="0"><span data-position="7191" data-size="101">ACCORD Study Group. (2010). Effects of intensive blood-pressure control in type 2 diabetes mellitus. </span><em data-position="7292" data-size="0"><span data-position="7293" data-size="36">New England Journal of Medicine, 362</span></em><span data-position="7330" data-size="17">(17), 1575–1585. </span><a href="https://doi.org/10.1056/NEJMoa1001286" target="_blank" rel="noopener"><span data-position="7347" data-size="37">https://doi.org/10.1056/NEJMoa1001286</span></a></p><p class="part" data-startline="149" data-endline="149" data-position="7386" data-size="0"><span data-position="7386" data-size="213">Ambrosius, W. T., et al. (2014). The design and rationale of a multi-centre clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). </span><em data-position="7599" data-size="0"><span data-position="7600" data-size="19">Clinical Trials, 11</span></em><span data-position="7620" data-size="14">(5), 532–546. </span><a href="https://doi.org/10.1177/1740774514537404" target="_blank" rel="noopener"><span data-position="7634" data-size="40">https://doi.org/10.1177/1740774514537404</span></a></p><p class="part" data-startline="151" data-endline="151" data-position="7676" data-size="0"><span data-position="7676" data-size="95">Beckett, N. S., et al. (2008). Treatment of hypertension in patients 80 years of age or older. </span><em data-position="7771" data-size="0"><span data-position="7772" data-size="36">New England Journal of Medicine, 358</span></em><span data-position="7809" data-size="17">(18), 1887–1898. </span><a href="https://doi.org/10.1056/NEJMoa0801369" target="_blank" rel="noopener"><span data-position="7826" data-size="37">https://doi.org/10.1056/NEJMoa0801369</span></a></p><p class="part" data-startline="153" data-endline="153" data-position="7865" data-size="0"><span data-position="7865" data-size="148">Drawz, P. E., et al. (2017). Effect of intensive vs. standard clinic-based hypertension management on ambulatory blood pressure: A SPRINT substudy. </span><em data-position="8013" data-size="0"><span data-position="8014" data-size="16">Hypertension, 69</span></em><span data-position="8031" data-size="12">(1), 42–50. </span><a href="https://doi.org/10.1161/HYPERTENSIONAHA.116.07642" target="_blank" rel="noopener"><span data-position="8043" data-size="49">https://doi.org/10.1161/HYPERTENSIONAHA.116.07642</span></a></p><p class="part" data-startline="155" data-endline="155" data-position="8094" data-size="0"><span data-position="8094" data-size="106">Hu, J. R., &amp; Chang, T. I. (2021). Kidney outcomes in the SPRINT study: A kidney-centric narrative review. </span><em data-position="8200" data-size="0"><span data-position="8201" data-size="16">Hypertension, 78</span></em><span data-position="8218" data-size="14">(2), 293–303. </span><a href="https://doi.org/10.1161/HYPERTENSIONAHA.120.16835" target="_blank" rel="noopener"><span data-position="8232" data-size="49">https://doi.org/10.1161/HYPERTENSIONAHA.120.16835</span></a></p><p class="part" data-startline="157" data-endline="157" data-position="8283" data-size="0"><span data-position="8283" data-size="142">SPRINT MIND Investigators. (2019). Effect of intensive vs. standard blood pressure control on probable dementia: A randomised clinical trial. </span><em data-position="8425" data-size="0"><span data-position="8426" data-size="9">JAMA, 321</span></em><span data-position="8436" data-size="14">(6), 553–561. </span><a href="https://doi.org/10.1001/jama.2018.21442" target="_blank" rel="noopener"><span data-position="8450" data-size="39">https://doi.org/10.1001/jama.2018.21442</span></a></p><p class="part" data-startline="159" data-endline="159" data-position="8491" data-size="0"><span data-position="8491" data-size="153">Williamson, J. D., et al. (2019). Intensive vs. standard blood pressure control and cardiovascular disease outcomes: Final report of a randomised trial. </span><em data-position="8644" data-size="0"><span data-position="8645" data-size="36">New England Journal of Medicine, 380</span></em><span data-position="8682" data-size="17">(24), 1776–1786. </span><a href="https://doi.org/10.1056/NEJMoa1901281" target="_blank" rel="noopener"><span data-position="8699" data-size="37">https://doi.org/10.1056/NEJMoa1901281</span></a></p><p class="part" data-startline="161" data-endline="161" data-position="8738" data-size="0"><span data-position="8738" data-size="97">Wright, J. T., Jr., Williamson, J. D., Whelton, P. K., Snyder, J. K., Sink, K. M., Rocco, M. V., </span><span class="smartypants" data-position="8835" data-size="3">…</span><span data-position="8838" data-size="148"> &amp; Fine, L. J. (2015). A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine, 373(22), 2103–2116. </span><a href="https://doi.org/10.1056/NEJMoa1511939" target="_blank" rel="noopener"><span data-position="8986" data-size="37">https://doi.org/10.1056/NEJMoa1511939</span></a></p><p class="part" data-startline="163" data-endline="163" data-position="9025" data-size="0"><span class="ui-comment-inline-span" data-inline-comment-id="user-selection-highlight" data-position="9025" data-size="6">Wright</span><span data-position="9031" data-size="86">, J. T., et al. (2021). The SPRINT trial revisited: Updated results and implications. </span><em data-position="9117" data-size="0"><span data-position="9118" data-size="36">American Journal of Hypertension, 34</span></em><span data-position="9155" data-size="14">(5), 439–451. </span><a href="https://doi.org/10.1093/ajh/hpab022" target="_blank" rel="noopener"><span data-position="9169" data-size="35">https://doi.org/10.1093/ajh/hpab022</span></a></p></div>
            
  </main>
</body>
</html>

